In line with this concept, inhibition of TRPV4 activity reduced CD4+ and CD8+ T cell migration across the inflamed brain endothelium and therefore presents a potential strategy to modulate BBB dysfunction and T cell extravasation in MS (Fig. 6). Here, CD8A is linked to myeloid sarcoma.